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ABSTRACT 
This study aimed to investigate the levels of matrix metalloproteinase-8 (MMP-8) and 
tissue inhibitors of MMP-1 (TIMP-1) in saliva and serum samples of women with 
polycystic ovary syndrome (PCOS) and matched systemically healthy controls, with 
varying degrees of gingival inflammation. A total of 125 women were included in this 
study (PCOS; n=80, systemically healthy; n=45). Salivary levels of MMP-8 and 
MMP-8/TIMP-1 ratio were significantly elevated in women with PCOS, who also 
exhibited gingivitis compared to periodontally or systemically healthy women. No 
major changes were observed in salivary TIMP-1 levels with regards to PCOS. Serum 
levels of MMP-8 and MMP-8/TIMP-1 ratio were significantly higher in women with 
PCOS, irrespective of the presence of gingivitis, while there were no differences in 
TIMP-1 levels. A positive correlation was indicated between PD, BOP, PI and 
salivary or serum MMP-8 levels or MMP-8/TIMP-1 ratio in the case of PCOS, while 
a negative such correlation was revealed for TIMP-1 in systemically healthy women. 
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Increased levels of MMP-8 in saliva and serum seem to be more pronounced in 
women with PCOS, and potentiated in the presence of gingival inflammation. 
Alterations in MMP/TIMP system triggered by local and systemic inflammation may 
be implicated in the pathogenesis of PCOS, or the deterioration of its clinical 
presentation. 
 
INTRODUCTION 
Polycystic ovary syndrome (PCOS), or Stein-Leventhal syndrome, is one of the most 
common endocrine disorder affecting about 6.5 % to 8 % of women and 
heterogeneous with reproductive and metabolic dysfunction.1,2 Patients with PCOS 
are under a high risk for insulin-dependent diabetes,3 visceral obesity4 and 
cardiovascular disease.5 Changes in the ovarian extracellular environment such as 
follicular development, ovulation and subsequent formation and regression of the 
corpus luteum, as well as follicular atresia are regulated, in part, by the actions of a 
specific family of proteolytic enzymes known as the matrix metalloproteinases 
(MMPs).6 MMPs and their tissue inhibitors (tissue inhibitors of metalloproteinases, 
TIMPs) control the site and remodeling of the ovarian tissue, and are associated with 
a variety of physiological and pathological processes.7 PCOS is characterized by 
abnormalities of ovarian tissue degradation and alterations of MMP expression.8 It 
was previously demonstrated that serum MMP-9 concentrations and MMP-9/TIMP-1 
ratios were significantly higher in women with PCOS than those in systemically 
healthy women.7 An altered balance between serum levels of MMPs and TIMPs in 
women with PCOS has indeed recently been reported.9 MMPs and TIMPs are also 
produced locally in periodontium and altered levels of MMPs are associated with 
inflammation related with gingivitis and periodontitis.10,11 MMP-8 is a proteolytic 
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enzyme secreted mainly by neutrophils that is present in inflamed gingiva, gingival 
crevicular fluid (GCF), saliva and serum. MMP-8 can be activated both by host and 
bacterial enzymes.12 In several studies it was reported that GCF MMP-8 levels were 
found to differentiate between periodontal health and the conditions of gingivitis and 
periodontitis13,14 and plays an important role in periodontal tissue destruction.13 
Furthermore, especially serum MMP-8 and TIMP-1 levels may reflect systemic 
chronic inflammatory and immune responses.15-17 During the onset and progression of 
periodontal disease, at cellular level, increased secretion of cytokines and 
inflammatory markers such as interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor 
necrosis factor-α (TNF-α) results in the release of MMPs when gingival health 
progresses to disease.18 It was recently demonstrated that PCOS is particularly 
associated with the severity of gingival inflammation especially on the 
proinflammatory cytokines such as IL-6, IL-17, TNF-α.19-21 Moreover, higher levels 
of suspected periodontal pathogens, such as Porphyromonas gingivalis, and 
Fusobacterium nucleatum, and higher antibody responses to those, were observed in 
women with PCOS, particularly on the substrate of increased gingival inflammation.22  
Despite intense research, the pathophysiology of PCOS has not been fully 
understood. It has been suggested in recent studies that the MMP-TIMP system may 
be implicated in the pathogenesis of PCOS through regulating the degradation and 
turnover of ovarian extracellular matrix.23 Since saliva is a suitable biological analyte 
to study in a global manner the oral health state, including gingival inflammation24,25 
and since PCOS is a systemic condition, it was deemed that saliva is appropriate for 
the design of this case-control study. Therefore, the aim of the study is to investigate 
the salivary and serum levels of MMP-8 and TIMP-1 in females with PCOS and 
systemically healthy controls, in the presence or absence of gingivitis.  
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MATERIALS AND METHODS 
Study population and clinical examination 
The Ethics Committee of the Ege University approved the study protocol (13-5.1/13) 
and all patients received information on the study and signed the informed consent 
before the enrolment. The study was conducted in full accordance with ethical 
principles, including the World Medical Association’s Declaration of Helsinki, as 
revised in 2008 and conforms to STROBE guidelines for observational studies.26 In 
four study groups a total of 125 patients (45 women with PCOS and healthy 
periodontium, 35 with PCOS and gingivitis, 25 systemically and periodontally healthy 
women, and 20 systemically healthy women with gingivitis) were recruited from the 
outpatient clinic of the Department of Endocrinology, School of Medicine, Aydın 
Government Hospital, Turkey, between October 2012 and April 2013. For each 
individual participant, comprehensive medical and dental histories were completed. A 
diagnosis of PCOS was assigned according to the 2003 criteria by Rotterdam with the 
presence of at least two of the following: polycystic ovaries, oligomenorrhea and/or 
anovulation, hyperandrogenism (clinical and/or biochemical).27 Systemically healthy 
women were included as a control group with history of regular menstrual cycle, no 
clinical or biochemical sign of hyperandrogenism, and after verifying absence of 
PCOS by ultrasound examination. Patients were excluded if any of the following 
criteria were present; hyperandrogenism (tested by levels of 17-α-
hydroxyprogesterone), diabetes mellitus, hyperprolactemia, congenital adrenal 
hyperplasia, thyroid disorders, Cushing’s syndrome, hypertension, hepatic or renal 
dysfunction, BMI > 30 kg/m2, and cardiovascular diseases. None of the patients were 
using medications such as oral contraceptive agents, steroid hormones, insulin-
sensitizing drugs and antibiotics or anti-inflammatory drugs that could affect their 
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periodontal status during the last 6 months before inclusion in the study. Enrolled 
patients were referred to the clinic for clinical periodontal measurements including 
probing depth (PD), plaque index (PI),28 and the presence of bleeding on probing 
(BOP; +/-). BOP was assumed positive if it occurred within 15 seconds after 
application of the probe. Clinical periodontal measurements were recorded at 6 sites 
on each tooth except for third molars, using a Williams periodontal probe (Hu-Friedy, 
Chicago, IL). All clinical measurements were performed by a single calibrated 
examiner (AA). 
Patient selection was based on consensus report of the 1999 International Workshop 
for the Classification of Periodontal Diseases and Conditions.29 Diagnosis of 
gingivitis was assigned when BOP scores > 50 % of all sites, PD < 3 mm at 90 % of 
the measured sites and no more than one site had a PD > 4 mm or clinical attachment 
level (CAL) ≤ 1 mm, and no clinical and/or radiographic sign of periodontitis was 
evident. 
Collection and processing of saliva and serum 
All salivary samples were collected in the morning between 8:00 am and 9:00 am. 
The individuals were asked first to rinse their mouth with distilled water, before 
expectorating whole saliva into sterile 50 ml tubes for 5 min. The collected saliva-
containing tubes were then placed on ice, supplemented with EDTA-free Protease 
Inhibitor Cocktail (Roche Applied Science, Switzerland), and then centrifuged at 
10000 x g for 15 min at +4°C. The resulting supernatants were then immediately 
aliquoted and frozen at -80°C. For serum collection, a total of 5 ml of venous blood 
were taken into BD Vacutainer blood collection tubes with silicone-coated interior 
(BD Diagnostics, Franklin Lakes, NJ, USA) by a standard venipuncture method. The 
collected serum samples were left at room temperature to allow for blood clotting and 
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then centrifuged at 1500 x g for 15 min at +4°C, in order to remove the fibrin clot and 
other cellular elements. The serum samples were then immediately aliquoted and 
frozen at -80°C.  
MMP-8 analyses by immunofluorometric assay (IFMA) 
Salivary and serum levels of MMP-8 were analysed by a time-resolved IFMA using 
the methods previously described by Hanemaaijer et al, and Tuomainen et al.30,31 
MMP-8 specific antibodies 8708 (Medix Biochemica Oy Ab, Kauniainen, Finland) 
were used as the catching and 8706 (Medix Biochemica Oy Ab, Kauniainen, Finland) 
as the tracer antibody, which was labelled using europium-chelate. All samples were 
assayed in single. Then, samples were diluted in assay buffer consisted of 20 mM 
Tris-HCl (pH 7.5), 0.5 M NaCl, 5 mM CaCl2, 50 µM ZnCl2, 0.5 % bovine serum 
albumin, 0.05 % sodium azide, and 20 mg/L diethylenetriaminepentaacetic acid and 
incubated for 1 h, continued with the tracer antibody incubation for 1 h. 5 min after 
the addition of enhancement solution fluorescence was measured using a fluoremeter, 
(1234 Delfia Research Fluoremeter, Wallac, Turku, Finland). The specificity of the 
monoclonal antibodies30 against MMP-8 was the same as that of polyclonal MMP-8 
antibodies.30,32  
TIMP-1 analyses by enzyme-linked immunosorbent assay (ELISA)  
Enzyme-linked immunosorbent assay (ELISA) (Duoset ELISA Development 
Systems, R&D Systems, Minneapolis, USA) was used to evaluate salivary and serum 
levels of TIMP-1.33 All samples were assayed in duplicate. The ELISA kit was 
capable of detecting the active, pro-, complexed and fragmented forms of the studied 
TIMP-1 as mentioned by the manufacturer. MMP-8/TIMP-1 ratios were calculated as 
described previously as well.31  
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Statistical analysis 
A statistical software program (GraphPad Prism version 6.00c for Mac OS X, 
GraphPad Software, La Jolla California USA) was used for statistical analyses. The 
distribution of the variables was validated by D’Agostino-Pearson omnibus normality 
test. Comparisons between all groups for non-normal distributed variables (MMP-8, 
TIMP-1 levels and MMP-8/TIMP-1 ratios in serum and saliva) were performed by the 
Kruskal-Wallis test and Dunn’s test was used in order to correct for multiple 
comparisons. For normally distributed variables (age, PI, BOP and PD) one-way 
ANOVA test with Holm-Sidak’s multiple comparison test (family-wise significance 
and confidence level 0.05) was used. Correlations between BOP, PI scores, PD and 
biochemical data were analysed by Spearman's correlation test. All tests were 
performed at α= 0.05. 
 
RESULTS 
Clinical findings 
The clinical and demographic data of this patient population have been reported 
earlier.22 Briefly, there were no statistically significant differences in age between 
groups, whereas the clinical measurements of PI, BOP and PD were significantly 
higher in the gingivitis groups, than the periodontally healthy groups, either 
systemically healthy or with PCOS. Clinical periodontal parameters were similar in 
the gingivitis groups with or without PCOS. 
 
Salivary and serum levels of MMP-8 and TIMP-1 
The salivary and serum MMP-8, TIMP-1 levels and MMP-8/TIMP-1 ratios were 
investigated. In women with PCOS, salivary MMP-8 levels were significantly 
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elevated in gingivitis compared to periodontal health. No differences were found in 
systemically healthy group between periodontal health and gingivitis (Fig. 1A). In 
systemically healthy women, salivary TIMP-1 levels were significantly higher in 
periodontal health, compared to gingivitis. Nevertheless, no differences in TIMP-1 
levels were found between the two PCOS groups (Fig. 1B). Interestingly, the salivary 
MMP-8/TIMP-1 ratio was significantly higher in women with PCOS and gingivitis, 
compared to periodontal healthy women, with or without PCOS (Fig. 1C).  
The corresponding serum levels of MMP-8 and TIMP-1 were then 
investigated. MMP-8 levels were significantly higher in women with PCOS and 
gingivitis compared to systemically healthy women with gingivitis. Significantly 
elevated serum MMP-8 levels were also found in periodontally healthy women with 
PCOS, compared to systemically healthy women with gingivitis (Fig. 1D). Serum 
TIMP-1 levels were not significantly different among the study groups (Fig. 1E). 
Nevertheless, the serum MMP-8/TIMP-1 ratio was significantly higher in women 
with PCOS and gingivitis compared to systemically healthy women with gingivitis. It 
was also significantly higher in periodontally healthy women with PCOS, compared 
to systemically healthy women with gingivitis (Fig. 1F), following a trend similar that 
to MMP-8. 
 
Correlations 
The correlations of clinical variables including clinical periodontal parameters and 
salivary and serum biochemical data according to the systemic health status (PCOS or 
systemically healthy) are presented in Table 1. In the case of PCOS, a significant 
positive correlation was indicated between PD, BOP % and PI and MMP-8 levels or 
MMP-8/MMP-1 ratio in saliva. On the contrary, in the systemically healthy group, a 
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significant negative correlation was revealed between salivary TIMP-1 levels and PD, 
BOP % and PI, although a positive correlation was found between these clinical 
measurements and the MMP-8/MMP-1 ratio.  
Regarding serum, there was a positive correlation between MMP-8 levels or 
the MMP-8/TIMP-1 ratio and all clinical periodontal parameters in PCOS. However, 
these correlations were not seen in systemically healthy women, who exhibited 
instead a positive correlation between TIMP-1 levels in serum and BOP % or PI. 
 
DISCUSSION 
Matrix metalloproteinases have been implicated in various physiological and 
pathological processes including inflammatory response,16 cardiovascular diseases,34 
and ovarian dysfunction, as recently identified. In the present study, salivary and 
serum MMP-8, TIMP-1 levels and MMP-8/TIMP-1 ratio were analysed in patients 
with PCOS and systemically healthy controls. The two groups were very similar in 
terms of demographic and clinical periodontal parameters, apart from higher plaque 
and bleeding on probing scores in the gingivitis groups. We demonstrated that women 
with PCOS had elevated serum and saliva MMP-8 concentrations, particularly in the 
presence of gingival inflammation (i.e. gingivitis). While TIMP-1 levels in serum 
remained unaffected, in saliva these proved to be lower in systemically healthy 
women with gingivitis. Interestingly, the serum MMP-8/TIMP-1 ratio was elevated in 
women with PCOS, irrespective of the presence of gingivitis. Although MMP-8 and 
TIMP-1 concentrations in plasma samples have been evaluated in women with 
PCOS,9 salivary levels of MMP-8 and TIMP-1 in PCOS patients, and their 
association with gingival inflammation have not been previously demonstrated. The 
lack of differences in clinical periodontal parameters between the groups (PCOS or 
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systemically healthy) may imply a relationship between the elevated levels of MMP-8 
and PCOS. 
Gingivitis is a reversible condition associated with inflammation caused by the 
microbial biofilm accumulating on the tooth surfaces. If left untreated, gingivitis may 
progress to periodontitis in some individuals.35 Determination of the progression of 
the inflammatory lesion could be explained by differential host responses attributed to 
an individual’s susceptibility.36 Host derived inflammatory mediators, such as 
cytokines, and proteolytic enzymes, such as MMPs, are triggered and activated as a 
response to the bacterial infection.16,37 PCOS is characterized by chronic low-grade 
inflammation,38 and a prolonged low-grade inflammatory state can be caused by 
chronic infections such as gingivitis, which is a common condition seen in the general 
population worldwide. It was reported that gingivitis is frequently observed in patients 
with PCOS.19-21 It is postulated that such peripheral and ovarian inflammation might 
be the precursor for insulin resistance, hypothalamic-pituitary-ovarian dysfunction 
and anovulation.39 At least one-half of women with PCOS are obese,40 or insulin 
resistant and hyperinsulinemic, independent of obesity.41 Hence, obesity and diabetes 
could influence inflammatory status, which in turn may affect MMP-8, and TIMP-1 
levels. Therefore be noted that non-obese and non-diabetic patients were included in 
the present study. 
Regarding the association of PCOS with gingival inflammation, it was 
recently demonstrated that they appear to act synergistically on the production of pro-
inflammatory cytokines IL-6, IL-17 and TNF-α.20,21 Moreover, a reciprocal link 
between PCOS and oral health was reported by elevated salivary levels of the 
periodontal pathogens Porphyromonas gingivalis, Fusobacterium nucleatum and 
Tannerella forsythia levels in women with PCOS, particularly in the presence of 
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gingivitis.22 In addition, certain microorganisms, such as A. actinomycetemcomitans 
are highly associated to release and activation of MMP-8.42 In the present study, a 
positive association between clinical periodontal parameters and the salivary or serum 
levels of MMP-8 was revealed particularly in the case of PCOS but not in 
systemically healthy individuals. This positive correlation could denote an additive 
effect of PCOS on salivary MMP-8 levels, especially in the presence of gingival 
inflammation and since both systemically healthy groups showed similar levels of this 
biomarker. Reversely, systemically healthy women exhibit a negative correlation 
between TIMP-1 and clinical periodontal parameters, which is not observed in PCOS. 
Thus, considering the findings of the present study together with the previous data,20-
22
 it is suggested that PCOS has a confounding effect on gingival inflammation, with 
regards to the MMP-TIMP system in serum and saliva.  
It was previously demonstrated that TIMPs are protective against periodontal 
disease, by controlling MMP activity and are found in higher levels in saliva of 
periodontally healthy individuals.43 The higher TIMP-1 levels in systemically healthy 
women with healthy periodontium, compared to women with gingivitis, confirm these 
previous findings. Still, the similar salivary TIMP-1 levels in both PCOS groups may 
reveal a direct or indirect effect of this underlying systemic condition on periodontal 
tissues. Although the mechanism still remains obscure, decreased salivary TIMP-1 
levels in PCOS might imply decreased protection against MMP-8 activity and 
increased susceptibility to gingival inflammation. On the other hand, serum TIMP-1 
levels were not significantly different among groups in the present study, which is in 
line with previous reports.9 As molecules present in saliva could be either produced 
locally or derive from serum,44 the discrepancy in TIMP-1 levels between serum and 
saliva observed here could be attributed to local (oral) rather than systemic 
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production. Based on the present findings it is apparent that in the absence of gingival 
inflammation, TIMP-1 levels are not consumed and can keep up the anti-MMP-8 
protective shield, whereas already during gingivitis salivary TIMP-1 is being 
consumed and levels in saliva are reduced. Since gingivitis is a less severe or initial 
form of periodontal pathology, it may not be surprising that the changes detected in 
saliva do not match with corresponding changes in serum. Nevertheless, one should 
not exclude the possibility that such changes may eventually occur as well in serum, 
once periodontal disease progresses.  
The MMP-8/TIMP-1 ratio could be an indicator of the proteolytic activity 
within a biological medium. It was recently demonstrated, as a salivary biomarker, 
this ratio correlated significantly with clinical periodontal variables, such as PD and 
BOP.37 Our findings are also showing a significant positive correlation between PD, 
BOP, PI and salivary MMP-8/TIMP-1 ratios. These could be due to the degree of 
gingival inflammation, as postulated by previous studies.37 It has also been 
demonstrated that women with PCOS had elevated serum concentrations of MMP-2, 
MMP-9 and MMP-9/TIMP-1 ratio, compared to healthy women with regular 
ovulation.7,45 Lewandowski et al. reported similar results with significantly higher 
serum concentrations of MMP-2, MMP-9 and TIMP-1 levels in women with PCOS 
than healthy controls.8 
Elevated serum and saliva levels of the MMP-8/TIMP-1 ratio can be 
indicators of a critical equilibrium between MMPs and TIMPs that determines 
extracellular matrix degradation, and alterations in the MMPs/TIMPs ratios may lead 
to disease. Fundamental aspect of ovarian function (such as secretion of hormones 
and production of oocytes), require dynamic, extensive, cyclic tissue remodeling. 
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Therefore, deregulation of their balance may contribute to ovarian pathologies 
characterized by improper follicular development and atresia, such as PCOS. 
It can be concluded from the present study that increased levels of MMP-8 and 
MMP-8/TIMP-1 ratio in saliva and serum seem to be more pronounced in women 
with PCOS, and potentiated by gingival inflammation. While the examined 
population is of relatively young age and free of periodontitis, the elevated 
concentrations of MMP-8 pose a risk for future disease progression. Although the 
present findings highlight an important interplay between PCOS and gingival 
inflammation, it is difficult to conclude on the exact underlying mechanism for the 
involvement of the MMP-8-TIMP-1 system in this, due to the case-control nature of 
the study. Longitudinal prospective studies would be more suitable to probe this link, 
and reveal if there is a causal or occasional relationship.  
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Table 
 
Table 1. Correlation analysis between clinical periodontal parameters and both serum 
and salivary MMP-8, TIMP-1 levels and MMP-8/TIMP-1 ratios. Significant 
correlations are shown in bold face. 
 
 
Serum 
 
Saliva 
PD BOP% PI  PD BOP% PI 
PC
O
S 
MMP-8 r 
0.274 0.249 0.285  0.341 0.404 0.422 
p 0.014 0.026 0.010  0.002 0.000 0.000 
TIMP-1 r 
0.006 -0.042 -0.029  -0.002 -0.136 -0.104 
p 0.959 0.713 0.798  0.985 0.229 0.360 
MMP-8/TIMP-1 r 
0.239 0.234 0.261  0.315 0.411 0.414 
p 0.032 0.037 0.019  0.004 <0.001 <0.001 
Sy
st
em
ic
a
lly
 
H
ea
lth
y 
MMP-8 r 
-0.242 -0.201 -0.179  0.152 0.217 0.155 
p 0.113 0.190 0.246  0.318 0.152 0.310 
TIMP-1 r 
0.191 0.392 0.331  -0.454 -0.418 -0.428 
p 0.213 0.009 0.028  0.002 0.004 0.003 
MMP-8/TIMP-1 r 
-0.285 -0.332 -0.293  0.436 0.502 0.471 
P 0.061 0.028 0.054  0.003 <0.001 0.001 
 
PD = Probing pocket depth (mm), BOP% = Bleeding on probing (%), PI = Plaque Index. 
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Figure Legend 
Figure 1. Metalloproteinase-8 levels in serum and saliva 
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Metalloproteinase-8 levels in serum and saliva from PCOS with periodontal health (Ph) 
(n=45); PCOS with gingivitis (Pg) (n=35); systemically healthy with periodontal health (Hh) 
(n=24); systemically healthy with gingivitis (Hg) (n=20). The individual values represent; 
(A); MMP-8 levels in saliva, (B); TIMP-1 levels in saliva, (C); MMP-8/TIMP-1 levels in 
saliva, (D); MMP-8 levels in serum, (E); TIMP-1 levels in serum, (F); MMP-8/TIMP-1 
levels in serum in both groups. The horizontal lines and numbers in the boxplots represent 
the median values for each patient group and the whiskers represent the 5-95 percentiles. * p 
< 0.05, ** p = 0.01, *** p < 0.001 **** p <  0.0001 
 
 
